Additional Analyses Show Custirsen Lowered Serum Clusterin Levels in CRPC Patients

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OncoGenex Pharmaceuticals Inc. presented results from additional exploratory analyses of the phase III SYNERGY trial, demonstrating that custirsen treatment significantly lowered serum clusterin levels from baseline in men with metastatic castrate-resistant prostate cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login